HCW Biologics (HCWB) stock saw a massive rally on Monday after the clinical-stage biopharmaceutical company announced new developments. The company highlighted its development of second-generation, pembrolizumab-based immunotherapeutics against solid tumors, specifically pancreatic and ovarian cancer. This was made with the company’s novel and proprietary TRBC product discovery and development platform technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr. Hing Wong, founder and CEO of HCW Biologics, said, “In our preclinical studies, our second-generation checkpoint inhibitor outperformed pembrolizumab in immune-cell activation and expansion, enhancement of immune cell infiltration into the tumors, and immune cell cytotoxicity against cancer cells.”
HCW Biologics plans to reveal more details from its study of its new checkpoint inhibitor next month. Dr. Wong will hold a presentation going over the data during the College of Pharmacy Seminar Series being held by Nova Southeastern University, located in Fort Lauderdale, Florida. This will take place on Sept. 12, 2025, meaning investors will want to keep an eye on HCWB stock that day.
HCW Biologics Stock Movement Today
HCW Biologics stock was up 54.16% in pre-market trading on Monday, following a 4.25% rally on Friday. However, the shares were still down 80.66% year-to-date and 79.33% over the past 12 months. Today’s news came with heavy trading, as some 18 million shares changed hands, compared to a three-month daily average of about 87,000 units.
Is HCW Biologics Stock a Buy, Sell, or Hold?
Turning to Wall Street, coverage of HCW Biologics is thin. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates HCWB stock a Neutral (43) with a $4 price target. It cites “significant financial and operational challenges” as reasons for this stance.
